Robert Iannone, AstraZeneca’s head of immune-oncology research, on the unpredictable immunotherapy market.
September 22, 2017Share
September 21, 2017Share
Novo expects Victoza and semaglutide to gain momentum.
Novo aims for GLP-1 sales growth in China
September 18, 2017Share
EU regulators recommend PARP inhibitor Zejula
Tesaro’s Zejula primed for EU approval, battle with AZ
September 14, 2017Share
AZ talks up Bydureon data, GLP-1 and glucagon combo
September 13, 2017Share
Semaglutide is under review in Europe and US.
Novo showcases next-gen GLP-1 at EASD
September 12, 2017Share
ESMO 2017 round up: BMS and AZ bounce back
September 9, 2017Share
Tagrisso on target to be EGFR+ lung cancer standard
September 8, 2017Share
Regulator is exploring safety of immunotherapy combinations in blood cancer
FDA puts hold on AZ and Celgene immunotherapy trials